{"downloaded": true, "htmlmade": false, "full": {"id": "33541288", "source": "MED", "pmid": "33541288", "pmcid": "PMC7863429", "fullTextIdList": {"fullTextId": "PMC7863429"}, "doi": "10.1186/s12885-021-07828-2", "title": "Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to\u00a0standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer)\u00a0with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).", "authorString": "Thureau S, Marchesi V, Vieillard MH, Perrier L, Lisbona A, Leheurteur M, Tredaniel J, Culine S, Dubray B, Bonnet N, Asselain B, Salleron J, Faivre JC.", "authorList": {"author": [{"fullName": "Thureau S", "firstName": "S\u00e9bastien", "lastName": "Thureau", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Radiation Oncology & Medical Physics Department, Henri-Becquerel Comprehensive Cancer Center, rue d'Amiens, F-76 000, Rouen, France. sebastien.thureau@chb.unicancer.fr."}, {"affiliation": "EA4108 QuantIf Litis, University of Rouen, 22 boulevard Gambetta, 76000, Rouen, France. sebastien.thureau@chb.unicancer.fr."}]}}, {"fullName": "Marchesi V", "firstName": "Vincent", "lastName": "Marchesi", "initials": "V", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Academic Radiation Oncology & Brachytherapy Department, Lorraine Institute of Cancerology - Alexis-Vautrin Comprehensive Cancer Center, 6 avenue de Bourgogne, 54519, Vand\u0153uvre-l\u00e8s-Nancy, France."}}}, {"fullName": "Vieillard MH", "firstName": "Marie-H\u00e9l\u00e8ne", "lastName": "Vieillard", "initials": "MH", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Rheumatology Department, University Hospital of Lille, 2 avenue Oscar Lambret, 59 000, Lille, France."}}}, {"fullName": "Perrier L", "firstName": "Lionel", "lastName": "Perrier", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "UMR CNRS 5824, L\u00e9on B\u00e9rard Comprehensive Cancer Center, 28 rue laennec, 69 373, Lyon, France."}}}, {"fullName": "Lisbona A", "firstName": "Albert", "lastName": "Lisbona", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Academic Radiation Oncology & Brachytherapy Department, Institut de Canc\u00e9rologie de l'Ouest - Ren\u00e9 Gauducheau Comprehensive Cancer Center, Boulevard Professeur Jacques Monod, 44805, Saint-Herblain, France."}}}, {"fullName": "Leheurteur M", "firstName": "Marianne", "lastName": "Leheurteur", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Medical Oncology Department, Henri-Becquerel Comprehensive Cancer Center, rue d'Amiens, 76000, Rouen, France."}}}, {"fullName": "Tredaniel J", "firstName": "Jean", "lastName": "Tredaniel", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Pneumology Department, University Hospital of Paris (Groupe hospitalier Paris Saint-Joseph), 185 Rue Raymond Losserand, 75014, Paris, France."}}}, {"fullName": "Culine S", "firstName": "St\u00e9phane", "lastName": "Culine", "initials": "S", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Medical Oncology Department, University Hospital of Paris (Saint-Louis Hospital), 1 avenue Claude Vellefaux, 75010, Paris, France."}, {"affiliation": "Paris Diderot University, 16 rue Huchard, 75018, Paris, France."}]}}, {"fullName": "Dubray B", "firstName": "Bernard", "lastName": "Dubray", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Radiation Oncology & Medical Physics Department, Henri-Becquerel Comprehensive Cancer Center, rue d'Amiens, F-76 000, Rouen, France."}, {"affiliation": "EA4108 QuantIf Litis, University of Rouen, 22 boulevard Gambetta, 76000, Rouen, France."}]}}, {"fullName": "Bonnet N", "firstName": "Na\u00efma", "lastName": "Bonnet", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Unicancer, 101, rue de Tolbiac, F-75654, Paris, France."}}}, {"fullName": "Asselain B", "firstName": "Bernard", "lastName": "Asselain", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Unicancer, 101, rue de Tolbiac, F-75654, Paris, France."}}}, {"fullName": "Salleron J", "firstName": "Julia", "lastName": "Salleron", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Biostatistics Department, Institut de Canc\u00e9rologie de Lorraine - Alexis-Vautrin Comprehensive Cancer Center, 6 avenue de Bourgogne, F-54519, Vand\u0153uvre-l\u00e8s-Nancy, France."}}}, {"fullName": "Faivre JC", "firstName": "Jean-Christophe", "lastName": "Faivre", "initials": "JC", "authorId": {"@type": "ORCID", "#text": "0000-0002-2617-3562"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Academic Radiation Oncology & Brachytherapy Department, Lorraine Institute of Cancerology - Alexis-Vautrin Comprehensive Cancer Center, 6 avenue de Bourgogne, 54519, Vand\u0153uvre-l\u00e8s-Nancy, France."}}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0002-2617-3562"}}, "dataLinksTagsList": {"dataLinkstag": "supporting_data"}, "journalInfo": {"issue": "1", "volume": "21", "journalIssueId": "3105166", "dateOfPublication": "2021 Feb", "monthOfPublication": "2", "yearOfPublication": "2021", "printPublicationDate": "2021-02-01", "journal": {"title": "BMC cancer", "ISOAbbreviation": "BMC Cancer", "medlineAbbreviation": "BMC Cancer", "NLMid": "100967800", "ISSN": "1471-2407", "ESSN": "1471-2407"}}, "pubYear": "2021", "pageInfo": "117", "abstractText": "<h4>Background</h4>Stereotactic Body Radiation Therapy (SBRT) is an innovative modality based on high precision planning and delivery. Cancer with bone metastases and oligometastases are associated with an intermediate or good\u00a0prognosis. We assume that prolonged survival rates would be achieved if both the primary tumor and metastases are controlled by local treatment. Our purpose is to demonstrate, via a multicenter randomized phase III trial, that local treatment of metastatic sites with curative intent with SBRT associated of systemic standard of care treatment would improve the progression-free survival in patients with solid tumor (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases compared to patients who received systemic standard of care treatment alone.<h4>Methods</h4>This is an open-labeled randomized superiority multicenter phase III trial. Patients with up to 3 bone-only metastases will be randomized in a 1:1 ratio.between Arm A (Experimental group): Standard care of treatment & SBRT to all bone metastases, and Arm B (Control group): standard care of treatment. For patients receiving SBRT, radiotherapy dose and fractionation depends on the site of the bone metastasis and the proximity to critical normal structures. This study aims to accrue a total of 196 patients within 4\u2009years. The primary endpoint is progression-free survival at 1\u2009year, and secondary endpoints include Bone progression-free survival; Local control; Cancer-specific survival; Overall survival; Toxicity; Quality of life; Pain score analysis, Cost-utility analysis; Cost-effectiveness analysis and Budget impact analysis.<h4>Discussion</h4>The expected benefit for the patient in the experimental arm is a longer expectancy of life without skeletal recurrence and the discomfort, pain and drastic reduction of mobility and handicap that the lack of local control of bone metastases eventually inflicts.<h4>Trials registration</h4>ClinicalTrials.gov NCT03143322 Registered on May 8th 2017. Ongoing study.", "affiliation": "Radiation Oncology & Medical Physics Department, Henri-Becquerel Comprehensive Cancer Center, rue d'Amiens, F-76 000, Rouen, France. sebastien.thureau@chb.unicancer.fr.", "publicationStatus": "epublish", "language": "eng", "pubModel": "Electronic", "pubTypeList": {"pubType": ["Clinical Trial Protocol", "research-article", "Journal Article"]}, "grantsList": {"grant": {"grantId": "PHRC K 15 149", "agency": "Minist\u00e8re des Finances et des Comptes Publics", "orderIn": "0"}}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Carcinoma, Non-Small-Cell Lung", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}, {"abbreviation": "SU", "qualifierName": "surgery", "majorTopic_YN": "Y"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Bone Neoplasms", "meshQualifierList": {"meshQualifier": [{"abbreviation": "SC", "qualifierName": "secondary", "majorTopic_YN": "N"}, {"abbreviation": "SU", "qualifierName": "surgery", "majorTopic_YN": "Y"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Breast Neoplasms", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}, {"abbreviation": "SU", "qualifierName": "surgery", "majorTopic_YN": "Y"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Lung Neoplasms", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}, {"abbreviation": "SU", "qualifierName": "surgery", "majorTopic_YN": "Y"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Prostatic Neoplasms", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}, {"abbreviation": "SU", "qualifierName": "surgery", "majorTopic_YN": "Y"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Prognosis"}, {"majorTopic_YN": "N", "descriptorName": "Combined Modality Therapy"}, {"majorTopic_YN": "N", "descriptorName": "Radiosurgery", "meshQualifierList": {"meshQualifier": {"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "Y"}}}, {"majorTopic_YN": "N", "descriptorName": "Survival Rate"}, {"majorTopic_YN": "N", "descriptorName": "Follow-Up Studies"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Multicenter Studies as Topic"}, {"majorTopic_YN": "N", "descriptorName": "Randomized Controlled Trials as Topic"}, {"majorTopic_YN": "N", "descriptorName": "Clinical Trials, Phase III as Topic"}]}, "keywordList": {"keyword": ["Neoplasm metastasis", "Prostatic neoplasms", "Breast neoplasms", "Lung Neoplasms", "Bone Metastases", "Radiosurgery", "Stereotactic Radiotherapy", "Mesh: Oligometastases"]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1186/s12885-021-07828-2"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7863429"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7863429?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "0", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2021-05-10", "dateOfCreation": "2021-02-05", "firstIndexDate": "2021-02-06", "fullTextReceivedDate": "2021-02-08", "dateOfRevision": "2021-05-10", "electronicPublicationDate": "2021-02-04", "firstPublicationDate": "2021-02-04"}, "htmllinks": "https://europepmc.org/articles/PMC7863429", "abstract": "<h4>Background</h4>Stereotactic Body Radiation Therapy (SBRT) is an innovative modality based on high precision planning and delivery. Cancer with bone metastases and oligometastases are associated with an intermediate or good\u00a0prognosis. We assume that prolonged survival rates would be achieved if both the primary tumor and metastases are controlled by local treatment. Our purpose is to demonstrate, via a multicenter randomized phase III trial, that local treatment of metastatic sites with curative intent with SBRT associated of systemic standard of care treatment would improve the progression-free survival in patients with solid tumor (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases compared to patients who received systemic standard of care treatment alone.<h4>Methods</h4>This is an open-labeled randomized superiority multicenter phase III trial. Patients with up to 3 bone-only metastases will be randomized in a 1:1 ratio.between Arm A (Experimental group): Standard care of treatment & SBRT to all bone metastases, and Arm B (Control group): standard care of treatment. For patients receiving SBRT, radiotherapy dose and fractionation depends on the site of the bone metastasis and the proximity to critical normal structures. This study aims to accrue a total of 196 patients within 4\u2009years. The primary endpoint is progression-free survival at 1\u2009year, and secondary endpoints include Bone progression-free survival; Local control; Cancer-specific survival; Overall survival; Toxicity; Quality of life; Pain score analysis, Cost-utility analysis; Cost-effectiveness analysis and Budget impact analysis.<h4>Discussion</h4>The expected benefit for the patient in the experimental arm is a longer expectancy of life without skeletal recurrence and the discomfort, pain and drastic reduction of mobility and handicap that the lack of local control of bone metastases eventually inflicts.<h4>Trials registration</h4>ClinicalTrials.gov NCT03143322 Registered on May 8th 2017. Ongoing study.", "Keywords": ["Neoplasm metastasis", "Prostatic neoplasms", "Breast neoplasms", "Lung Neoplasms", "Bone Metastases", "Radiosurgery", "Stereotactic Radiotherapy", "Mesh: Oligometastases"], "pdflinks": "https://europepmc.org/articles/PMC7863429?pdf=render", "journaltitle": "BMC cancer", "authorinfo": ["Thureau S", "Marchesi V", "Vieillard MH", "Perrier L", "Lisbona A", "Leheurteur M", "Tredaniel J", "Culine S", "Dubray B", "Bonnet N", "Asselain B", "Salleron J", "Faivre JC"], "title": "Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to\u00a0standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer)\u00a0with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS)."}